Home > Search Results

Results: 21 to 26 of 26

Clear

OBJECTIVES: To update the evidence for the safety of synthetic disease-modifying antirheumatic drugs (sDMARDs), glucocorticoids (GC) and biological DMARDs (bDMARDs) in patients with rheumatoid arthritis (RA) to inform the European League Against Rheumatism (EULAR) recommendations for the management of RA.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2014

This review assessed the effectiveness of drug treatments in preventing bone erosion (determined from X-rays) in rheumatoid arthritis. The authors concluded that cyclosporine, infliximab, sulphasalazine, leflunomide, methotrexate, parenteral gold, corticosteroids, auranofin and IL-1-RA are more effective than placebo. This conclusion appears reliable. Conclusions about relative effectiveness of different drugs were derived from indirect comparisons and may not be reliable.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2003

The authors concluded that withdrawal of disease-modifying antirheumatic drugs (DMARDs) in patients with established rheumatoid arthritis increased the risk of flare-up or deterioration. Patients with established rheumatoid arthritis, but adequate symptom control with DMARDs, should normally continue to receive treatment. Although the authors' conclusions reflected the evidence, the limited evidence available means that they should be interpreted with some caution.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2010

The authors concluded that there was insufficient data available to evaluate the comparative effectiveness of DMARDs. However, there was evidence to suggest that DMARDs improved symptoms associated with juvenile idiopathic arthritis. Further trials were needed. Based on such diverse and limited evidence, the authors' conclusions seem appropriate, but potential for language and reviewer bias should be considered.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2011

The authors concluded that starting disease-modifying antirheumatic drugs early in the course of rheumatoid arthritis may reduce long-term joint damage. Overall, this was a well-conducted review and the authors’ cautious conclusion appears to reflect the evidence from studies of limited quality.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2006

The review assessed treatment with two or more disease-modifying anti-rheumatic drugs (DMARDs) compared with a single DMARD for rheumatoid arthritis. The authors concluded that the balance of beneficial and adverse effects is most favourable with methotrexate plus either sulphasalazine and/or antimalarial drugs, or tumour necrosis factor inhibitors. The evidence presented is not sufficient to support definitive conclusions favouring particular treatments.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2005

Systematic Reviews in PubMed

See all (54)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...